Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Personalizing health care: feasibility and future implications (CROSBI ID 227626)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Godman, B ; Finlayson, AE ; Cheema, PK ; Zebedin-Brandl, E ; Gutiérrez-Ibarluzea, I ; Jones, J ; Malmström, RE ; Asola, E ; Baumgärtel, C ; Bennie, M et al. Personalizing health care: feasibility and future implications // Bmc medicine, 11 (2013), 1; 179-x. doi: 10.1186/1741-7015-11-179

Podaci o odgovornosti

Godman, B ; Finlayson, AE ; Cheema, PK ; Zebedin-Brandl, E ; Gutiérrez-Ibarluzea, I ; Jones, J ; Malmström, RE ; Asola, E ; Baumgärtel, C ; Bennie, M ; Bishop, M ; Bucsics, A ; Campbell, S ; Diogene, E ; Ferrario, A ; Fürst, J ; Garuoliene, K ; Gomes, M ; Harris, K ; Haycox, A ; Herholz, H ; Hviding, ; , Jan, S ; Kalaba, M ; Kvalheim, C ; Laius, O ; Lööv, SA ; Malinowska, K ; Martin, A ; McCullaghL, Nilsson, F ; Paterson, K ; Schwabe, U ; Selke, G ; Sermet, C ; Simoens, S ; Tomek, D ; Vlahović-Palčevski, V ; Voncina, L ; Wladysiuk, M ; van Woerkom, M ; Wong-Rieger, D ; Ali, R ; Gustafsson, LL.

engleski

Personalizing health care: feasibility and future implications

Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer’s perspective to provide future guidance. Multiple findings including general considerations ; influence of pharmacogenomics on response and toxicity of drug therapies ; value of biomarker tests ; limitations and costs of tests ; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients

Biomarkers ; Drug development ; Genomics ; Genotyping ; Healthcare policy ; Pharmacogenetics precision medicine ; Personalized medicine ; Health authorities ; Rational use of medicines ; Reimbursement ; Targeted treatments

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

11 (1)

2013.

179-x

objavljeno

1741-7015

10.1186/1741-7015-11-179

Povezanost rada

Javno zdravstvo i zdravstvena zaštita

Poveznice
Indeksiranost